{"drugs":["Nplate","Romiplostim"],"mono":{"0":{"id":"929155-s-0","title":"Generic Names","mono":"Romiplostim"},"1":{"id":"929155-s-1","title":"Dosing and Indications","sub":[{"id":"929155-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Idiopathic thrombocytopenic purpura, chronic:<\/b> initial: 1 mcg\/kg (actual body weight) SUBQ once weekly, adjusted weekly in increments of 1 mcg\/kg to achieve platelet count of 50 x 10(9)\/L or greater; MAX weekly dose 10 mcg\/kg<\/li><li><b>Idiopathic thrombocytopenic purpura, chronic:<\/b> if, following 4 weeks of therapy at the maximum weekly dose of 10 mcg\/kg SUBQ, the platelet count is not adequate to control bleeding, discontinue therapy and continue monitoring platelets for 2 weeks following discontinuation<\/li><\/ul>"},{"id":"929155-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},{"id":"929155-s-1-6","title":"Dose Adjustments","mono":"<ul><li>platelet count greater than 200 x 10(9)\/L for 2 consecutive weeks, reduce dose by 1 mcg\/kg<\/li><li>platelet count greater than 400 x 10(9)\/L, do not dose and monitor weekly platelet counts; after platelets fall to less than 200 x 10(9)\/L resume at a dose reduced by 1 mcg\/kg<\/li><\/ul>"},{"id":"929155-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Idiopathic thrombocytopenic purpura, chronic<br\/>"}]},"3":{"id":"929155-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929155-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"929155-s-3-10","title":"Precautions","mono":"<ul><li>antibody development has been reported; if suspected, contact Amgen (1-800-772-6436) for assays to detect neutralizing antibodies to romiplostim and thrombopoietin<\/li><li>failure to respond or maintain a response may occur; neutralizing antibodies to romiplostim may be present; discontinue treatment if platelet count does not increase to a clinically sufficient level after 4 weeks at the highest dose<\/li><li>hepatic impairment, chronic; portal venous thrombosis has been reported<\/li><li>myelodysplastic syndrome; risk of disease exacerbation and progression to acute myelogenous leukemia<\/li><li>thrombocytopenia, any cause other than chronic immune thrombocytopenia; use not recommended<\/li><li>thrombotic and thromboembolic complications may result from excessive platelet count increases; romiplostim should not be used to normalize platelet counts<\/li><li>report adverse events to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929155-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"929155-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"929155-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain (11%), Diarrhea (17%), Indigestion (7%), Nausea (13%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (26%), Backache (13%), Myalgia (14%), Pain in limb (13%)<\/li><li><b>Neurologic:<\/b>Dizziness (17%), Headache (35%), Insomnia (16%), Paresthesia (6%)<\/li><li><b>Respiratory:<\/b>Epistaxis (32%), Upper respiratory infection (17%)<\/li><li><b>Other:<\/b>Fatigue (33%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Acute myeloid leukemia, Bleeding (12%), Myelofibrosis, Normal reticulin, Increased, Popliteal artery thrombosis, Thrombosis<\/li><li><b>Hepatic:<\/b>Portal vein thrombosis<\/li><li><b>Other:<\/b>Acute myeloid leukemia<\/li><\/ul>"},"6":{"id":"929155-s-6","title":"Drug Name Info","sub":{"0":{"id":"929155-s-6-17","title":"US Trade Names","mono":"Nplate<br\/>"},"2":{"id":"929155-s-6-19","title":"Class","mono":"<ul><li>Hematopoietic<\/li><li>Thrombopoietin Receptor Agonist<\/li><\/ul>"},"3":{"id":"929155-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929155-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929155-s-7","title":"Mechanism Of Action","mono":"Romiplostim, an Fc-peptide fusion protein (peptibody), increases platelet production through binding and activation of the thrombopoietin (TPO) receptor, a mechanism similar to endogenous TPO.<br\/>"},"8":{"id":"929155-s-8","title":"Pharmacokinetics","sub":{"3":{"id":"929155-s-8-26","title":"Excretion","mono":"dependent on the thrombopoietin receptor on platelets <br\/>"},"4":{"id":"929155-s-8-27","title":"Elimination Half Life","mono":"1 to 34 days (median: 3.5 days) <br\/>"}}},"9":{"id":"929155-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>administer subQ only.<br\/><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>use a small-volume syringe with 0.01-mL graduations and verify the syringe contains the correct dose<\/li><li>reconstitute vials with correct volume of preservative-free sterile water for injection and gently swirl and invert, do not aggressively agitate or shake<\/li><li>do not reconstitute with bacteriostatic water for injection<\/li><li>once reconstituted, romiplostim must be administered within 24 hours; discard any unused portion<\/li><li>may be used with other medications, including corticosteroids, danazol, azathioprine, intravenous immunoglobulin (IVIG), and anti-D immunoglobulin, which may be reduced or discontinued if the platelet count is 50 x 10(9)\/L or greater<\/li><\/ul><\/li><\/ul>"},"10":{"id":"929155-s-10","title":"Monitoring","mono":"<ul><li>CBC with platelet count; at baseline, weekly during dose adjustment phase, monthly after platelet count has been stable (50 x 10(9) or greater) for at least 4 weeks without dose adjustment, and weekly for at least 2 weeks after treatment discontinuation<\/li><li>lack or loss of response; assess for antibodies to romiplostim and other causes<\/li><\/ul>"},"11":{"id":"929155-s-11","title":"How Supplied","mono":"<b>Nplate<\/b><br\/>Subcutaneous Powder for Solution: 250 MCG, 500 MCG<br\/>"},"13":{"id":"929155-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to continue avoiding situations or medications which increase the risk of bleeding, even with therapy.<\/li><li>Drug may cause headache, dizziness, insomnia, myalgia, arthralgia, extremity pain, abdominal pain, dyspepsia, and paresthesia.<\/li><li>Advise patient to call healthcare professional if a scheduled dose is missed, as missing a dose may increase the risk of bleeding.<\/li><\/ul>"}}}